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he Year in Molecular Imaging
ric A. Osborn, MD, PHD,* Farouc A. Jaffer, MD, PHD†
oston, Massachusetts
olecular imaging aims to enable personalized medicine via imaging-specific molecular and cellular
argets that are relevant to the diagnosis and treatment of disease. By providing in vivo readouts of
iological detail, molecular imaging complements traditional anatomical imaging modalities to allow:
) visualization of important disease-modulating molecules and cells in vivo; 2) serial investigations to
mage evolutionary changes in disease attributes; and 3) evaluation of the in vivo molecular effects of
iotherapeutics. The added information garnered bymolecular imaging can improve risk assessment and
rognosticative studies, this is of particular benefit in the management of cardiovascular disease
CVD). (J AmColl Cardiol Img2010;3:1181–95)©2010by theAmericanCollegeofCardiology Foundatione
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t tholecular imaging investigations of cardiovas-
ular disease (CVD) continue to increase each
ear. Over the past year, significant gains in
linical applications and new technology have
een achieved in vascular and myocardial im-
ging. In this update, we have the privilege to
ighlight recent outstanding clinical and trans-
ational molecular imaging studies of CVD.
ascular Imaging
therosclerosis. Atherosclerosis remains a
ominant focus for CVD molecular imaging
tudies. This field is driven by the quest to
dentify biologically high-risk “vulnerable”
laques (e.g., heightened plaque inflammation,
eovascularization, or apoptosis). Molecular
maging, therefore, complements traditional
natomical imaging approaches that identify
laque structure and composition.
rom the *Cardiology Division, Beth Israel Deaconess Medical Cen
nd the †Cardiovascular Research Center, Cardiology Division, and
etts General Hospital, Harvard Medical School, Boston, Massachu
edical Institute Early Career Award, American Heart Associa
ational Institutes of Health grant RO1 HL-108229. Dr. Jaffer w
eports that he has no relationships to disclose. The authors regre
ould not be included due to space limitations.anuscript received June 17, 2010; revised manuscript received AugusClinical molecular imaging studies of ath-
rosclerosis have grown substantially in recent
ears. The 2 leading clinical platforms remain
8F-fluorodeoxyglucose (18FDG) imaging of
laque metabolic activity/inflammation by
ositron emission tomography (PET), and ul-
rasmall superparamagnetic iron oxide (USPIO)
anoparticle-enhanced cardiac magnetic res-
nance (CMR) of plaque macrophages. These
odalities primarily interrogate the carotid
rteries and larger vascular beds, although
ecent preliminary reports suggest the poten-
ial for noninvasive coronary plaque imaging.
LINICAL 18FDG PET MOLECULAR IMAGING
TUDIES OF ATHEROSCLEROSIS. 18FDG is a
lucose analog trapped intracellularly by meta-
olically active cells, and therefore enables
ET-based detection of metabolism. 18FDG
as been used extensively in cancer and myo-
ardial viability studies. Pioneering work from
Harvard Medical School, Boston, Massachusetts;
nter for Molecular Imaging Research, Massachu-
s. This work was supported by a Howard Hughes
Scientist Development Grant #0830352N, and
prior consultant for VisEn Medical. Dr. Osborn
at additional excellent molecular imaging studiest 26, 2010, accepted September 7, 2010.
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1182he last decade demonstrated that 18FDG could
nable PET imaging of inflamed subsets of carotid
theromata of human subjects. Subsequent cor-
elational analyses established a link between
8FDG signals and plaque macrophages, or in-
ammation. Consistent with the widespread abil-
ty to perform clinical 18FDG PET imaging, the
umber of large-vessel atherosclerosis metabo-
ism/inflammation studies has grown substan-
ially in the last several years.
Several recent 18FDG plaque investigations have
hed new light on the clinical utility, pathophysiology,
nd spatial distribution of plaque metabolism/
nflammation. In an observational 18FDG PET/
omputed tomography (CT) study of 932 cancer
atients, increased 18FDG uptake (mean large-vessel
laque target-to-background ratio [TBR] 1.7) was
he strongest predictor of a future vascular event,
hich occurred in 1.6% of patients at a median
ollow-up time of 29 months (1). Importantly, the
8FDG signal was 4-fold more predictive of a future
ascular event compared with the degree of plaque
alcification noted on coregistered CT. A retrospec-
ive study of 200 patients demonstrated a correlation
etween cardiovascular risk factors and the number of
8FDG-positive plaques, and an inverse association be-
ween statin therapy and 18FDG-positive plaques (2).
Figure 1. PET/CT Imaging of Coronary Arterial Inﬂammation/Me
Suppression of myocardial 18F-ﬂuorodeoxyglucose (18FDG) was obta
images of (A) 18FDG positron emission tomography (PET) signal (ar
PET/CT image showing elevated 18FDG signal overlying a calciﬁed c
raphy showing severe left anterior descending coronary artery (LAD
Medicine, from Wykrzykowska et al. (7).In new pathophysiological studies, 18FDG
laque signals rarely overlapped with plaque calci-
cation, further suggesting that CT-detected calci-
cation may indicate a “burnt-out” plaque pheno-
ype. 18FDG plaque uptake was greater in patients
ith a history of coronary artery disease (CAD) and
lso associated with the inflammatory serum bi-
markers matrix metalloproteinase (MMP)-3 and
MP-9 (3). In multimodal 18FDG PET/CT and
MR studies of carotid plaques, 1 CMR study
ound that lipid-rich plaques had higher 18FDG
ignal intensities than collagen-rich or calcified
laques (4), whereas another study noted weak
orrelations between 18FDG plaque signals and
laque compositional parameters derived from CT
nd CMR (5). Lastly, a study of 10 carotid endar-
erectomy patients further linked 18FDG uptake to
laque inflammation (6). The inflammatory mes-
enger ribonucleic acid markers macrophage CD68,
athepsin K, matrix metalloproteinase (MMP)-9,
nd interleukin-18 positively correlated with the
8FDG TBR, with CD68 having the strongest
ssociation (r  0.71, p  0.02).
In an exciting preliminary advance, 18FDG
ET/CT enabled the noninvasive detection of cor-
nary plaque metabolism/inflammation (Fig. 1) (7).
ackground suppression of the typically intense
olic Activity via 18FDG
d by using a special high-fat diet prior to imaging. Representative
s), (B) cardiac computed tomography (CT) axial slice, (C) Fusion
nary artery (arrows), and (D) correlative invasive coronary angiog-
sease (arrows). Reprinted, by permission of the Society of Nucleartab
ine
row
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1183yocardial 18FDG signal was performed by having
atients consume a low-carbohydrate, high-fat
eal the night before, and then imbibe a vegetable
il drink prior to the study. In subjects with good
yocardial suppression, focal 18FDG signal (albeit
t limited resolution) was detected in CT-
emarcated coronary arterial segments, and tended
o be more prevalent in patients with angiographi-
ally confirmed CAD. Prospective studies are
eeded to determine whether 18FDG measures of
oronary plaque inflammation will predict coronary
vents.
LINICAL MOLECULAR CMR STUDIES OF PLAQUE
NFLAMMATION. USPIO are superparamagnetic
extranated nanoparticles that are phagocytosed by
laque macrophages, and therefore can report on
arotid plaque inflammation on T2-weighted CMR
tudies. Recent studies from the investigative group
n Cambridge have added new insights into human
laque inflammation. In the ATHEROMA (Ator-
astatin Therapy: Effects on Reduction of Macro-
hage Activity) trial, USPIOs were utilized to
eport on differential changes in plaque inflamma-
ion when 47 patients were randomized to high-
ose or low-dose statin pharmacotherapy (8). Com-
ared with atorvastatin 10 mg daily, atorvastatin 80
g daily significantly reduced USPIO-based plaque
nflammation on carotid CMR (Fig. 2). Further-
ore, high-dose, but not low-dose, statin therapy
educed cerebral microemboli detected on con-
omitantly obtained transcranial Doppler studies.
emarkably, these differences were detectable
fter only 12 weeks, thus providing insight into
he rapid clinical benefits noted in the MIRACL
Myocardial Ischemia Reduction with Aggressive
holesterol Lowering) and PROVE-IT (Prava-
tatin or Atorvastatin Evaluation and Infection
herapy) statin trials (9,10). The ATHEROMA
tudy demonstrates the power of molecular im-
ging to provide a biological readout for athero-
clerosis pharmacotherapies.
In a small cross-sectional study of subjects with
arotid atherosclerosis (stenosis 50%), Howarth
t al. (11) demonstrated that symptomatic patients
ad significantly more quadrants of USPIO-based
acrophage inflammation compared to asymptom-
tic patients (75% vs. 32%, p  0.01). Further
tudies may determine whether USPIO enhance-
ent in asymptomatic patients will portend a
igher stroke risk.
EW BIOLOGICAL INSIGHTS. The past year wit-
essed major advances in visualizing plaque inflam- aation, angiogenesis, apoptosis, oxidative stress,
nd calcification. In addition, hybrid imaging strat-
gies such as PET/CT, PET/CMR, and opti-
al/CT imaging broadened our understanding of
hese processes by providing coregistered molecular
nd structural detail of atheromata.
NFLAMMATION. In an integrated PET/CT dual-
arget molecular imaging study, the macrophage-
vid iodinated nanoparticle CT contrast reporter
N1177) detected plaque inflammation 2 h after
njection in atheroma-bearing rabbits (12). A mod-
rately strong correlation of N1177 uptake was
resent in comparison to 18FDG PET signal (r 
.61) and macrophage density on immunohisto-
hemistry (r  0.63). Worthley et al. (13) utilized
erial PET imaging of inflamed rabbit aortas to
how continued 18FDG uptake when a fatty diet
as sustained, and diminished 18FDG signal when
nimals were returned to a nonatherogenic diet.
Using contrast-enhanced ultrasound with P-selec-
in and vascular cell adhesion molecule (VCAM)-1
argeted microbubbles, Kaufmann et al. (14) demon-
trated that atheroma inflammation could be imaged
rior to the development of advanced lesions.
Amirbekian et al. (15) utilized a “positive” con-
rast CMR-detectable gadolinium chelate (P947)
ovalently linked to an MMP peptide sequence to
isualize plaque MMP expression in apolipoprotein
–deficient (ApoE/) mice. A 2-fold greater
ignal enhancement was noted over the control
scrambled peptide sequence) probe P1135. Imag-
ng of plaque MMP presence in ApoE- and low-
ensity lipoprotein–receptor dual-knockout mice
as also demonstrated using micro–single-photon
mission computed tomography (SPECT) imaging
f 99mTc-derivatized MMP inhibitor (16).
In an integrated PET/CT murine study, Laiti-
en et al. (17) utilized the clinically tested, integrin
v3-targeted tracer
18F-Galacto-RGD to identify
ellular (macrophage  endothelial cell) inflamma-
ion and neoangiogenic vasculature in atheroma.
nterestingly, the 18F-Galacto-RGD enhance-
ent associated primarily with macrophages, as
eovessels were uncommon in plaques from the
ouse model. Unlike 18FDG, the 18F-Galacto-
GD agent does not target the myocardium and
hus may ultimately enable low-background,
oninvasive PET imaging of coronary plaque
nflammation.
EW INFLAMMATION IMAGING AGENTS FOR ATH-
ROSCLEROSIS. To image VCAM-1 expression in
theroma, Nahrendorf et al. (18) developed 3 18F-
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1184abeled small VCAM-1 affinity ligands for
ET/CT imaging. The tetrameric peptide 18F-4V
rovided the highest specificity and affinity for
CAM-1, and enabled its noninvasive detection in
urine plaques. Statin-treated animals demon-
trated less in vivo plaque uptake of 18F-4V. 18F-4V
lso deposited in preliminary studies of myocardial
nfarction (MI) and cardiac transplant rejection, 2
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Figure 2. Molecular CMR of Carotid Plaque Inﬂammation Follow
Representative T2*-weighted left common carotid artery imaging befo
tion at baseline (A and B), 6 weeks (C and D), and 12 weeks (E and F)
yellow arrowhead), indicating plaque macrophages. (C and E) Pre-USP
retention before each round of imaging (red arrowhead). (D) Minimal
with reduced plaque inﬂammation. (F) At 12 weeks, even less USPIO e
pared for the 2 treatment groups at baseline, 6, and 12 weeks with 95
line, showing less USPIO effect and thus higher signal). CMR  cardiaciseases with augmented VCAM-1 expression. aNew agents to image atherosclerotic cysteine
rotease activity were developed and evaluated us-
ng integrated fluorescence molecular tomography
FMT)/CT (19). Three near-infrared fluorescence
NIRF) protease-activatable nanosensors of differ-
nt sizes (5 to 40 nm) and pharmacokinetics were
valuated, but with identical oligo-L-lysine cleavage
ites. Although the 5-nm agent showed faster
High Dose
ek
9 12 15
High-Dose Statin Treatment
d after ultrasmall superparamagnetic iron oxide (USPIO) administra-
Baseline USPIO effect is present (signal loss on T2*-weighted image,
ignal is similar at each imaging time point, signifying loss of tissue
IO signal loss is observed by 6 weeks (blue arrowhead), consistent
is present (blue arrowheads). (G) Signal intensity change (∆SI) com-
nﬁdence intervals; low-dose (red line) and high-dose (dashed blue
gnetic resonance. Reproduced, with permission, from Tang et al. (8).e
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1185ron oxide–containing nanoparticle) demonstrated
he strongest NIRF in murine plaques. In vivo
MT, a noninvasive tomographic imaging ap-
roach, detected strong PS-40 NIRF signals in the
ortic roots of ApoE/ mice. Statin therapy re-
ulted in diminished PS-40 signals in atheroma.
Lipinski et al. (20) developed a new macrophage-
pecific molecular CMR agent using a phospholipid
anoparticle containing gadolinium, the fluoro-
hrome NBD for target validation, and a biotinyl-
ted antibody to the human macrophage scavenger
eceptor B (CD36). In vitro confocal fluorescence
nd mass spectroscopy studies demonstrated strong
ptake of the agent by macrophages. Ex vivo CMR
f aortic plaques from patients also demonstrated
ptake of the agent by human macrophages. This
robe may expand the clinical options to image
laque macrophages beyond USPIO-CMR and
8FDG-PET.
Tekabe et al. (21) developed a new radiolabeled
racer that imaged the receptor for advanced glyca-
ion end products (RAGE), a molecule that partic-
pates in plaque inflammation. The imaging agent
as created by radiolabeling a RAGE antibody
ragment with technecium-99m. Planar gamma
mages revealed focal uptake in the thoracic aorta in
poE/ mice that was not noted when using a
ontrol antibody.
POPTOSIS. Zhao et al. (22) employed 99mTc-
nnexin A5, a clinically tested apoptosis imaging
gent, and 18FDG to covisualize plaque apoptosis and
etabolism/inflammation. Ex vivo analyses demon-
trated that both 99mTc-annexin A5 (apoptosis) and
8FDG (inflammation/metabolism) deposition in
urine plaques increased similarly from ages 10 to 25
eeks, and was greatest in cholesterol-fed ApoE/
ice.
EOVASCULARIZATION. Gadofluorine-M is an
mpiphilic compound with high R1 relaxivity that
rovides excellent T1-weighted CMR plaque con-
rast. To further explore its microscopic localization
n atherosclerosis, Sirol et al. (23) crafted a carbo-
yanine fluorescent derivative of gadofluorine-M.
n atheroma-bearing rabbits injected with this de-
ivative, confocal microscopy and detailed histolog-
cal analyses linked gadofluorine-M deposition and
D31 plaque neovessels, as well as the degree of
laque macrophages.
XIDATIVE STRESS. Myeloperoxidase (MPO) activity
n plaques was visualized in vivo by the positive-contrast
MR agent bis-5HT-DTPA(Gd) (24). MPO cata-yzes the formation of hypochlorite and other reactive pxidants that are linked to plaque progression and
omplication. A detailed study in rabbits established
hat bis-5HT-DTPA(Gd) enhanced atheromata on
1-weighted CMR, in comparison to control
gents. Findings were corroborated by biochemical
ssays of MPO activity in the vessel wall, and by
mmunohistochemical studies of plaque sections.
ntriguingly, MPO activity localized at plaque
houlders, further implicating this enzyme in plaque
estabilization.
ALCIFICATION. Calcified nodules and microcalci-
cations are now appreciated as a consequence of
ascular inflammation, but the mechanism of bone
ineral deposition remains unclear. In ApoE/
ice with advanced renal failure, Aikawa et al. (25)
nvestigated the role of the elastolytic protease
athepsin S (CatS) on arterial and aortic valve
alcification. Multichannel intravital fluorescence
maging was performed after coinjection of a spe-
ialized CatS protease-activatable NIRF probe; os-
eogenic activity was detected by a spectrally dis-
inct fluorescent bisphosphonate agent (OsteoSense
80, VisEn Medical, Bedford, Massachusetts). Ten
eeks after nephrectomy, CatS-deficient mice
ApoE/CatS/) exhibited significantly less ar-
erial and aortic valve calcification than control
poE/CatS/ mice. Intriguingly, plaque size
nd macrophage content were similar in both ne-
hrectomized groups, suggesting that CatS was
pecifically involved in osteogenesis, possibly by
eleasing elastin peptide degradation products that
romote local mineralization. Proteolytic enzymes,
uch as CatS and MMP, may represent biomarkers
f calcific and plaque remodeling that may provide
io-efficacy readouts for future anticalcific
herapies.
IO-EVALUATION OF ATHEROSCLEROSIS PHARMA-
OTHERAPIES. Emerging atherosclerosis therapeu-
ics are primarily biologics, and therefore a biological
eadout of drug efficacy may be advantageous com-
ared with classical structural atheroma measure-
ents. In addition to the clinical ATHEROMA trial
8), discussed in previous text, several recent preclinical
tudies from the last year illustrate the utility of
olecular imaging to interrogate the biological effects
f anti-inflammatory therapies.
In a comprehensive report, Fujimoto et al. (26)
tilized an MMP imaging agent (99mTc conjugated
o the broad-spectrum, MMP-inhibiting macrocy-
lic compound RP805) to study the effects of statin
herapy on plaque inflammation. Plaque MMP
resence on in vivo micro-SPECT imaging was
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1186educed with just 1 month of fluvastatin therapy. In
dual-isotope SPECT protocol, Haider et al. (27)
etected both broad-spectrum MMP activity and
poptosis in inflamed rabbit plaques via com-
ined 99mTc-RP805 (MMP) and 111In-annexin
5 imaging (macrophages/apoptosis). Strong
MP and annexin A5 plaque signals on SPECT
maging were diminished by 1 month of fluva-
tatin therapy or withdrawal of the high-
holesterol diet. In addition, this study demon-
trated a moderate correlation (r  0.62) between
he MMP and annexin SPECT signals, as well as
ith plaque macrophages, MMP-9, and
UNEL apoptotic cells.
NTRAVASCULAR CORONARY ARTERY–TARGETED
OLECULAR IMAGING OF INFLAMMATION. Al-
hough clinical molecular imaging has made signif-
cant inroads into exploring molecular and cellular
argets in larger vascular beds (carotid, aorta, iliac),
trategies to interrogate the coronary arteries are
imited. To address this need, a novel prototype
IRF intravascular catheter was developed and
ested for real-time sensing of plaque inflammation
n rabbit iliac arteries (of similar size to human
oronary arteries) (28). The NIRF catheter was
eveloped from a clinical intracoronary optical co-
erence tomography wire. Twenty-four hours be-
ore imaging, rabbits received a cysteine protease-
ctivatable NIRF agent (ProSense 750, 600 nmol/
g, VisEn Medical) to identify inflamed plaques.
eal-time catheter pullback revealed 500% in-
reases in the peak TBRs in ProSense 750 (VisEn
edical) rabbits compared with saline-injected
ubjects (Fig. 3). Notably, intravascular NIRF im-
ging was performed through blood, without the
eed for flushing, consistent with the favorable light
ransmission properties of the NIR window. The
vailability of a clinical intravascular NIRF catheter
ould accelerate the detection of biologically high-
isk coronary plaques.
neurysm. CLINICAL 18FDG PET IMAGING OF AB-
OMINAL AORTIC ANEURYSM. Elevated 18FDG
ignal occurs in subsets of aneurysms, and associates
ith inflammatory markers and possibly rapid ex-
ansion. Kotze et al. (29) recently applied 18FDG
ET/CT to evaluate advanced infrarenal abdomi-
al aortic aneurysms (AAAs) (diameter 5.4  0.8
m) in 14 men undergoing surveillance imaging.
lthough all AAAs had reasonably high 18FDG
ptake, the 2 aneurysms that exhibited inflamma-
ory changes based on CT criteria (periaortic fibro-
is) possessed significantly greater 18FDG signal
ctivity. The degree of CT calcification and the knitial AAA diameter did not correlate with 18FDG
ptake in this small-sized study.
In an illustrative case report, Reeps et al. (30)
onnected elevated 18FDG signals, inflammation, and
echanical instability in a patient with a small infra-
enal AAA (4.6-cm diameter) on a staging 18FDG
ET/CT scan. Just 6 months later, the asymptomatic
AA showed markedly increased 18FDG PET up-
ake in association with rapid aneurysm expansion
6.0-cm diameter). The patient underwent successful
rophylactic surgical repair and biopsies were obtained
rom areas of high and low 18FDG activity. In areas of
igh 18FDG activity, the tissue showed collagen and
lastin destruction, macrophage infiltration, and en-
anced MMP expression. Larger investigations of
8FDG PET imaging for identifying AAAs likely to
apidly progress and/or rupture are in progress.
EW EXPERIMENTAL IMAGING INSIGHTS. DeLeo
t al. (31) recently demonstrated the ability to
mage elevated MPO activity in an inflammatory
ntracranial aneurysmal disease model. Saccular in-
amed aneurysms created in rabbit carotid arteries
ere imaged at 48 h with a 3.0-T whole-body
linical CMR scanner using a paramagnetic MPO
ontrast agent (di-5-hydroxytryptamide of gado-
entetate dimeglumine). Compared with controls,
PO-specific signal was 30% enhanced in the
nflamed aneurysms and exhibited delayed tissue
ashout. This agent may be translatable to human
tudies of endovascular inflammation caused by
acrophage and neutrophil activity in atheroscle-
osis and other vascular inflammatory conditions.
Tedesco et al. (32) investigated the role of neovas-
ularization in murine AAA progression using a
IRF reporter targeted to the vascular endothelial
rowth factor (VEGF) receptor. At a time point
etween 21 and 28 days after angiotensin II–induced
neurysm formation, a NIRF Cy5.5-derivatized
ingle-chain VEGF homodimer was injected intrave-
ously. Two hours later, in situ, ex vivo and fluores-
ence images revealed NIRF signal in aneurysmal
egments. The NIRF signal reflecting AAA neovas-
ularization correlated well with the AAA diameter
easured on ultrasound (r  0.69). VEGF receptor
maging may represent a new surrogate marker for
ssessment of the progression and treatment of AAA.
HROMBOSIS. Clinical molecular imaging studies of
hrombosis. Vymazal et al. (33) recently published
he full phase II clinical results of EP-2104R, a
brin-targeted, gadolinium-derivatized peptide for
olecular CMR of thrombosis. Patients withnown venous (n 14) or arterial (n 38) thrombi
u
t
t
o
E
a
F
r
v
a
N
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 1 1 , 2 0 1 0
N O V E M B E R 2 0 1 0 : 1 1 8 1 – 9 5
Osborn and Jaffer
Year in Molecular Imaging
1187nderwent EP-2104R–enhanced CMR. For both
ypes of thrombi, EP-2104R increased the detec-
ion capability by enhancing thrombi not apparent
n noncontrast scans (Fig. 4). However, despite
P-2104R administration, 71% of venous thrombi
Figure 3. Real-Time Intravascular NIRF Detection of Atheroscler
(A) In vivo manual catheter pullback trajectory in the iliac arteries (
near-infrared ﬂuorescence (NIRF) agent showed strong ﬂuorescence
Medical] group, average target-to-background ratio [TBR] 6.8) in an
generated signiﬁcantly less NIRF signal. (E and F) Paired light and N
activity. (G) Saline-injected control rabbits again with minimal plaqu
iliac artery. Reproduced, with permission, from Jaffer et al. (28).nd 16% of arterial clots remained undetected. ourther investigations may optimize imaging pa-
ameters to showcase this approach beyond con-
entional, flow-based thrombosis diagnostic im-
ging methods (e.g., ultrasound, CT).
ew thrombosis imaging agents. Expanding on prior
Inﬂammation
ed arrow). (B and C) Rabbits injected with a protease-activatable
nals in vivo, through blood, without ﬂushing (Prosense750 [VisEn
raphically demarcated iliac plaques. (D) Saline-injected rabbits
signals in ex vivo arterial samples show enhanced NIRF protease
utoﬂuorescence. Ao  aorta; LIA  left iliac artery; RIA  rightosis
dott
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1188lood transglutaminase factor XIII (FXIIIa),
iserus et al. (34) developed a bimodal optical-
MR agent for FXIIIa. FXIIIa is a hallmark of
iologically acute thrombi, and is involved in fi-
rinolytic resistance. The authors linked a FXIIIa-
argeted oligopeptide substrate to gadolinium for
MR and to the fluorochrome rhodamine for
icroscopic localization. In murine carotid artery
hrombosis, immediate FXIIIa agent injection fol-
owed by CMR at 90 min revealed hyperintense
ignal at the thrombus border zones (contrast-to-
oise ratio [CNR] of 2.28), and was confirmed on
x vivo 2-photon rhodamine fluorescence micros-
opy. In contradistinction, older thrombi (24 to
8 h old) demonstrated virtually no signal enhance-
ent (CNR 0.11), consistent with the disappear-
nce of FXIIIa in older thrombi.
ascular injury. The ability to monitor the inflam-
atory response following vascular injury could
elp elucidate the pathogenesis of many diseases
ncluding graft arteriosclerosis, in-stent restenosis,
nd diabetic vasculopathies. In particular, MMPs
lay an important role in vascular remodeling fol-
owing injury. To track the MMP response in
xperimental vascular injury, Zhang et al. (35)
Figure 4. Molecular CMR of Fibrin-Rich Thrombi Using the Clini
(A) Right atrial thrombus is demonstrated in the right panel 24 h a
EP-2104R enhanced ﬁbrin-bearing irregular aortic atheromata and ﬁ
the left panel, an initially hidden left ventricular thrombus become
sists 24 h later (right panel). CMR  cardiac magnetic resonance. Rtilized the previously validated SPECT radiotracer v11In-RP782 to image broad-spectrum MMP ac-
ivity. At 2 to 4 weeks after guidewire mechanical
njury of the carotid artery in ApoE/ mice,
P782 was injected, and micro-SPECT/CT imag-
ng was performed 2 h later. Focal, strong signal
as evident in the injured left carotid artery seg-
ent, but not the right-sided sham-treated vessel.
P782 uptake correlated directly with hyperplastic
essel–wall area expansion. Competitive inhibition
xperiments with excess unlabeled tracer dimin-
shed RP782 uptake. RP782 may also enable im-
ging MMP presence within atherosclerotic
laques as an indicator of inflammation and
nstability.
In an inflammatory protease imaging study, Sh-
th et al. (36) utilized an intravascular NIR fluores-
ence endoscope to visualize cysteine protease ac-
ivity in the injured aorta of rats. The group
eveloped an intriguing normalization strategy to
ccount for blood pool signal attenuation that
requently confounds quantitative real-time endo-
ascular NIRF imaging. Capitalizing on the ratio of
NIRF signals with matched blood attenuation
roperties, the effects of light absorption and red
lood cell scattering were effectively canceled, pro-
gent EP-2104R
EP-2104R delivery with peripheral hyperenhancement. In addition
ous pleuritis of the right lung. (B) Prior to EP-2104R injection in
parent 2 h after EP-2104R administration (center panel) and per-
duced, with permission, from Vymazal et al. (33).cal A
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1189ntervening blood layer size between the emitting
ource and detection probe. Subsequent experi-
ents in rats with focal aortic wall injury confirmed
he ability of this technique to discriminate local
ascular protease activity (NIRF).
yocardial Imaging
yocardial infarction. PHARMACOLOGICAL STUD-
ES. Biological imaging readouts of therapies di-
ected against adverse myocardial remodeling re-
ain a priority area for molecular imaging of MI.
wo recent studies by van den Borne et al. (37,38)
llustrate the molecular and cellular effects of key
eart failure therapies such as angiotensin-
onverting enzyme (ACE) inhibitors, aldosterone
Up
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Figure 5. In Vivo Molecular Imaging of Myocardial Remodeling
(A) Micro-CT, micro-SPECT, and SPECT/CT fusion images in control m
onstrate 9mtechnetium-labeled Cy5.5-RGD peptide (Tc-CRIP) uptake
no signiﬁcant Tc-CRIP uptake, however intense Tc-CRIP signal was p
then diminished at 4 and 12 weeks. (C) Quantitative Tc-CRIP activit
zone and noninfarcted base. CT computed tomography; SPECT 
permission, from van den Borne et al. (38).ntagonists, and angiotensin receptor blockers. Fol- bowing induction of MI by coronary artery occlu-
ion, mice were treated for 4 weeks with 1-, 2-, or
-drug combinations of captopril (an ACE inhibi-
or) or losartan (an angiotensin receptor blocker) or
pironolactone (an aldosterone antagonist). Mice
hen underwent micro-SPECT/CT imaging with
n integrin-specific 99mTc-labeled RGD peptide
onjugated to a Cy5.5 fluorescent agent (termed
RIP) that identifies myofibroblast-related colla-
en deposition in the post-infarction scar (Fig. 5)
37). Peak CRIP signal 2 to 4 weeks after infarction
as significantly reduced in an additive fashion by
equential blockade of the renin-angiotensin-
ldosterone axis, and corresponded with improved
chocardiographic left ventricular function and di-
inished histological collagen deposition. Radiola-
eks 4 weeks 12 weeks
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5 .021 .0007
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ns ns
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(top row) or mice 4 weeks after anterior MI (bottom row) dem-
lusively in infarcted mice. Explanted hearts from (B) controls had
nt in infarcted mice 2 weeks after myocardial infarction (MI) that
s greatest in the apical infarct, followed by the mid peri-infarct
gle-photon emission computed tomography. Reproduced, with we
.00
.00
via
ice
exc
rese
y wa
sineled CRIP noninvasively identified myocardial
fi
t
k
N
o
s
(
e
h
w
C
i
v
o
i
c
t
m
r
r
p
(
v
(
m
p
o
d
g
i
l
d
a
h
d
m
T
a
m
e
b
d
m
d
t
p
h
m
m
f
(
i
v
C
w
l
T
o
c
p
N
b
i
w
C
b
a
k
i
9
h
9
s
c
s
l
i
C
p
d
m
t
e
v
b
R
p
r
a
t
b
e
fi
S
k
(
t
t
p
c
N
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 1 1 , 2 0 1 0
N O V E M B E R 2 0 1 0 : 1 1 8 1 – 9 5
Osborn and Jaffer
Year in Molecular Imaging
1190brosis following MI, and its uptake is responsive
o clinically beneficial neurohumoral antagonists
nown to limit adverse cardiac remodeling.
EW BIOLOGICAL INSIGHTS. In contrast to previ-
us beliefs that circulating monocytes undergo end-
tage differentiation upon tissue entry, Swirski et al.
39) identified a large splenic reservoir of undiffer-
ntiated monocytes that are liberated after MI,
ome to the site of injury, and actively engage in
ound healing. The team utilized multimodal
MR, FMT, and intravital microscopic molecular
maging methods to track monocyte migration in
ivo. This new paradigm suggests that a prominent
rgan source of inflammatory cells can be recruited
n response to local injury and participate in myo-
ardial healing. Modulating this cascade may mo-
ivate future therapies that coerce beneficial inflam-
atory cell profiles to elicit favorable cardiac
emodeling.
A dual-contrast molecular CMR technique has
ecently been employed to concurrently image acute
ost-MI mid-myocardial apoptosis and necrosis
40). Apoptosis was detected using a previously
alidated annexin-tagged cross-linked iron oxide
AnxCLIO-Cy5.5, an R2 agent similar to earlier
entioned clinical USPIOs) that identifies phos-
hatidylserine residues exposed on the membranes
f apoptotic cells. Necrosis was detected using a
elayed enhancement protocol and the fluorescent
adolinium agent Gd-NBD. In murine infarcts
nduced by 35 min of temporary coronary artery
igation, cardiomyocyte necrosis and apoptosis were
iscretely visualized on in vivo multicontrast CMR
t an early time point (4 to 6 h). Capitalizing on the
igh spatial resolution of CMR, geographic mural
ifferences in the infarct were noted. In the mid-
yocardium of the infarct zone, large regions of
2*-mediated AnxCLIO-Cy5.5 signal (reflecting
poptosis) were visible. In contrast, the mid-
yocardium was negative for delayed-gadolinium
nhancement (necrosis). Necrotic zones identified
y Gd-NDB enhancement localized to the suben-
ocardium. This study identified post-reperfusion
id-myocardial areas of apoptotic, but viable, car-
iomyocytes that might be salvageable by new,
argeted therapies, offering a new focus for im-
rovement of post-MI reperfusion injury and
ealing.
Sosnovik et al. (41) additionally studied chronic
yocardial apoptosis, a key feature of post-infarct
yocardial remodeling. Utilizing a murine heart
ailure model characterized by chronic, low-grade
1% to 2%) apoptosis with scant necrosis, mice were entravenously injected with AnxCLIO-Cy5.5 for in
ivo CMR and ex vivo fluorescence imaging. By
MR, myocardial pockets of AnxCLIO-Cy5.5
ere observed in the subendocardium, and corre-
ated strongly with apoptotic caspase-3 activity.
his technology might be applied in various forms
f chronic heart failure, including infarct-related
ardiomyopathy, to better identify subjects likely to
rogress to end-stage heart failure.
EW MOLI AGENTS. A new, high-affinity, collagen-
inding imaging agent for scintigraphic detection of
nfarct fibrosis was developed (termed collagelin,
ith a Kd of 1.1 10
7 M for type I collagen) (42).
ollagelin was discovered and synthesized from a
acterial peptide library using an antibody against
ntiglycoprotein VI (GPVI), an immunoadhesin
nown to bind type I and type III collagens. After
n vitro characterization, collagelin was labeled with
9mTc for in vivo SPECT imaging. Rats with prior
ealed MI (3 weeks old) received intravenous
9mTc-collagelin. In vivo SPECT imaging revealed
pecific isotope uptake in fibrotic areas dense in
ollagen fibers and showed minimal uptake in the
urrounding noninfarcted myocardium. The col-
agelin probe thus expands the armamentarium of
maging agents designed to assay fibrosis (37,38).
ell transplantation. Molecular imaging of trans-
lanted cell localization, function, proliferation,
urability, and cell fate/specificity is highly suited to
aximize the benefit of cardiovascular regenera-
ion. Strategies leveraging reporter gene and exog-
nous physical cell labeling approaches have re-
ealed substantial new insights into transplant cell
iology in the past year.
EPORTER GENE APPROACHES. Reporter gene ap-
roaches (i.e., incorporating a gene that encodes a
eceptor or substrate that can localize an imaging
gent) enable precise and specific tracking of cell
ransplants, providing accurate readouts of cell via-
ility and differentiation. Major reporter gene strat-
gies include bioluminescence imaging (BLI) of
refly luciferase (Fluc) gene expression and PET/
PECT imaging of herpes simplex virus thymidine
inase (HSV-tk) or the sodium-iodide symporter
NIS) gene expression.
Using BLI (Fluc), Li et al. (43) demonstrated
hat Sca-1–positive cardiac resident stem cells
ransplanted directly into mouse infarcts did not
rovide long-term cardiac engraftment nor benefit
ardiac function (Fig. 6). Higuchi et al. (44) utilized
IS-based PET reporter gene imaging to study thearly survival of cardiac-transplanted human endo-
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1191helial progenitor cells (EPCs). The study revealed
hat EPC survival was augmented by pretreatment
ith atorvastatin as well as cotransduction of the
PCs with VEGF (44). Swijnenburg et al. (45)
tilized BLI (Fluc) to compare acute and subacute
day 7) transplants of murine bone marrow mono-
uclear cells into mouse infarcts, finding low en-
raftment in both groups. The timing of cell trans-
lantation did not affect myocardial cell retention or
mpart significant benefits on cardiac function (45).
ai et al. (46) employed BLI to demonstrate that
uman adipose tissue–derived cells and stem cells
ould survive at least 4 months in an immunoprivi-
eged environment, and were associated with an
mprovement in myocardial function.
OMPARISON OF REPORTER GENE IMAGING VER-
US PHYSICAL CELL LABEL–BASED IMAGING. In a
ultimodal PET/CMR cardiac transplant study of
uman EPCs, Higuchi et al. (47) demonstrated the
omplementary roles of reporter gene imaging
NIS, 124I) and physical cell labeling with iron
xides. PET imaging revealed a loss of cell viability
y day 7 despite the persistence of iron oxide–
nduced signal void on CMR (Fig. 7). Histological
nalyses demonstrated the absence of transplanted
ells, corroborating the PET data, and also revealed
hat iron-laden macrophages were the likely source
f the residual CMR signal (47). In a similar
Figure 6. Reporter Gene Optical Imaging of CSC Transplantatio
(A) Fireﬂy luciferase reporter gene–labeled cardiac resident stem cel
day 2 that decreased markedly over 8 weeks of longitudinal trackin
over time and percentage donor cell survival. PBS  phosphate buffereultimodal study of post-MI athymic rats trans-
lanted with murine embryonic stem cells (ESCs)
xpressing the HSV-tk gene and also labeled with
uperparamagnetic iron oxides, Qiao et al. (48)
emonstrated ESC survival by PET imaging, but a
orresponding decrease in iron oxide CMR signal.
t 4 weeks, most iron oxide was histologically
resent within macrophages (48). Overall, although
ron oxide does not appear to be a reliable reporter
f long-term stem cell engraftment and survival, it
an provide a marker for early transplantation and is
linically approved for use in humans.
ARGE-ANIMAL DEMONSTRATION OF REPORTER
ENE IMAGING. In a swine study, Willmann et al.
49) utilized a clinical PET/CT scanner to image
yocardial transplants of human mesenchmyal
tem cells (MSCs) incorporating the HSV-tk gene.
uman MSCs (50–600 106) suspended in either
hosphate-buffered saline or a matrigel scaffold
ere implanted into the myocardium of swine.
maging of viable cells expressing the HSV-tk gene
as performed following injection of 9-(4-18F-
uoro-3-[hydroxymethyl]butyl)guanine (18F-
HBG). The matrigel scaffold increased the reten-
ion of viable MSCs (49). This study provides a
urther step towards clinical utilization of the
SV-tk reporter gene approach for human cardiac
SC) transplantation reveals prominent bioluminescence signal at
and C) Quantitative analyses of transplanted CSC signal changesn
ls (C
g. (Bd saline. Reproduced, with permission, from Li et al. (43).
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1192tudies, which may now be possible given a recent
easibility study in a cancer patient (50).
EW REPORTER GENE CONSTRUCTS. In a recent
dvance, Sun et al. (51) formulated a triple fusion
entiviral construct in ESCs consisting of Fluc,
SV-tk, and the monomeric red fluorescent protein
mRFP) reporter gene to provide a 3-phase imaging
eadout via bioluminescence, PET, and fluores-
ence imaging, respectively. The fluorescence capa-
ility enabled cell sorting/identification of ESCs
xpressing the triple construct. Monitoring trans-
lanted human ESC survival over 6 months using
n vivo BLI and PET imaging demonstrated long-
erm ESC viability with this approach. Noninvasive
eporter gene monitoring is a powerful technique
or stem cell tracking as only viable cells are cap-
ured, with the added benefit that daughter cells can
e tracked with equal efficacy during proliferation
ithout signal loss due to probe dilution.
Kuliszewski et al. (52) developed and validated a
eporter gene imaging strategy for contrast-enhanced
ltrasound. Bone marrow–derived rodent EPCs were
tably transfected with the gene for the cell surface
arker protein mouse H-2Kk. Ultrasound molecular
maging was performed by injecting microbubbles
onjugated to an anti–H-2Kk antibody. Imaging
Figure 7. Combined Reporter Gene Imaging (NIS-PET) and Phys
(A) Short-axis imaging of transplanted superparamagnetic iron oxide (S
endothelial progenitor cells (HEPCs) into rat hearts at days 1, 3, and 7.
PET uptake rapidly diminished to undetectable levels at day 7 (*p  0
time, present as early as day 3 (*p  0.001). This study highlights the
cell tracking. Abbreviations as in Figures 1, 2, and 6. Reprinted, by permemonstrated EPC growing within extracellular ma- Urix scaffolds implanted in the subcutaneous tissue of
ats. Although less sensitive than nuclear labeling
pproaches, this approach offers the potential for
ingle-modality functional and molecular assessment
f cardiac cell transplantation.
HYSICAL CELL LABELING METHODS. Physical cell
abeling approaches can utilize clinical imaging
argets such as USPIOs for CMR or 18FDG for
ET. As these labels are not durable or transplant
ell–specific over time, such approaches are likely to
e useful in documenting acute delivery of the cell
ransplant payload, and to provide a highly trans-
atable platform to optimize the clinical environ-
ent for maximal acute cell transplant retention.
Terrovitis et al. (53) utilized the metabolic imaging
gent 18FDG to study and manipulate acute cardiac-
erived stem cell transplant retention in Wistar rats.
8FDG PET demonstrated greater cell retention at
h when cell injections were sealed by fibrin glue
laced at the epicardial injection site, or when cells
ere injected during adenosine-induced bradycardia
r immediately following reversible cardiac arrest.
In addition, Adler et al. (54) developed a new
MR-based agent, gadofluorine M-Cy3 (GdFM-
y3, where Cy3 is a fluorochrome) for noninvasive
racking of stem cell engraftment. As opposed to
Cell Labeling (SPIOs–CMR) of Cell Transplantation
s) and NIS (sodium iodide symporter) reporter gene–labeled human
Mean ( SD) SPIO/CMR signals were stable over 7 days, whereas 124I
). (C and D) Autoradiography revealed similar loss of 124I uptake over
rences between reporter gene and physical cell label approaches for
on of the Society of Nuclear Medicine, from Higuchi et al. (47).ical
PIO
(B)
.001
diffeSPIO labels for CMR, gadofluorine is primarily a
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11931 relaxation agent and therefore imparts positive
MR contrast, which can be particularly advanta-
eous in low signal-to-noise ratio images. The
dFM-Cy3 paramagnetic probe forms micelles in
queous solutions that are retained within the cell
ytosol. The probe was tested by injection of
dFM-Cy3–labeled ESC-derived cardiac progen-
tor cells into infarcted zones of mouse hearts. Serial
.4-T CMR performed over 2 weeks revealed good
greement between the CMR-based signal and cell
dentification on fluorescent microscopy of excised
issues. Although this probe identifies cells early
fter transplantation, similar to other physical
gents, it may suffer from dilutional and nonspecific
ocalization in other cells over time.
ardiac transplant rejection. Current clinical diagno-
is of cardiac allograft rejection requires endomyo-
ardial biopsy. In addition to being invasive, endo-
yocardial biopsy–based diagnostics are limited by
ampling error. Noninvasive detection of cardiac
llograft rejection therefore remains an important
oal for transplant medicine. Two reports from the
ast year highlight progress in noninvasive molec-
lar CMR and optical imaging of the innate im-
une response in allograft rejection.
In a mouse model of heterotopic cardiac trans-
lantation, Christen et al. (55) detected allograft
ejection using noninvasive CMR and optical mo-
ecular imaging readouts for macrophage phagocy-
osis and cathepsin protease activity. Macrophages
ere sensed with a phagocytosable clinical-type
anoparticle imaging agent for CMR, and cathep-
in activity was sensed with a protease-activatable
IRF agent. Interestingly, early imaging at day 3
howed no difference between allografts and
sografts, presumably due to similar levels of
schemia-reperfusion injury. By day 7, allograft
ejection was the dominant inflammatory process.
n vivo imaging at day 7 demonstrated increased
acrophage enhancement on T2*-weighted CMR
nd increased NIRF cathepsin protease activity onJacobsson H. Assessment of inactive, fluorodeoxyglucoseoth the transplanted isograft group and the group
ith allografts implanted into genetically engi-
eered immune deficient mice.
In a second molecular and functional CMR study,
SPIOs (phagocytosable clinical-type nanoparticles
or CMR, 1.5- to 3.0-mg iron per animal) were
mployed in a rat abdominal heterotopic heart trans-
lant model to detect macrophage infiltration (56).
hroughout the rejection period, the USPIO signal
as observed to be heterogeneous, even in advanced
tages. As CMR can interrogate cardiac mechanics,
he authors performed additional measurements of
entricular function by myocardial tagging and strain
apping, and found a correspondence between the
xtent of macrophage infiltration and the circumfer-
ntial strain (Ecc). Based on these above studies,
acrophage presence and altered myocardial strain
ay indicate early allograft rejection prior to the onset
f frank left ventricular dysfunction.
utlook
olecular imaging studies are yielding unparalleled
nsight into in vivo cardiovascular biology. Experi-
entally, emphasis remains on developing highly
ensitive imaging agents with excellent safety and
harmacokinetic profiles, and on new detection
echnology designed to address unmet needs. Clin-
cal testing of promising molecular imaging agents
emains a top priority for the field. For molecular
maging to gain a solid foothold in CVD clinical
ractice, utility beyond functional and anatomical
maging will need to be demonstrated. In the near
erm, molecular imaging will play a key role in
ssessing the biological effects of CVD therapies. In
he mid-to-long term, molecular imaging should
mprove the risk stratification and the clinical man-
gement of many cardiovascular diseases.
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